Technology & Products

The Cytovia team and its advisors apply a translational approach to the latest development in immunology research. Our focus is on the targeted activation of Natural Killer (NK) cells through a variety of approaches - imcluding cell therapy and multispecific antibodies - to improve the clinical performance of immunotherapy in cancer and infectious diseases.


Cytovia is developing NKp46 multifunctional engagers with the potential for better disease control without hurting the healthy cells.